

OIPE JC139
 MAY 30 2002
 PATENT & TRADEMARK OFFICE

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO				<div style="text-align: center;">PATENT & TRADEMARK OFFICE</div> <div style="text-align: right;"><i>Complete if Known</i></div>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	09/975,932
				Filing Date	October 12, 1999
				First Named Inventor	CHAIN, Daniel G.
				Group Art Unit	1645
				Examiner Name	P. Duffy
Sheet	1	of	4	Attorney Docket Number	P-4815-US2

[illegible][illegible]


Examiner Signature	<i>Dorothy Croach</i>	Date Considered	<i>5/21/04</i>
-----------------------	-----------------------	--------------------	----------------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Please type a plus sign (+) inside this box →



Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/08A (10-96)

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

Of

4

Complete if Known

Application Number	09/402,820
Filing Date	October 12, 1999
First Named Inventor	CHAIN, Daniel G.
Group Art Unit	1543
Examiner Name	P. Duffy
Attorney Docket Number	P-4815-US

TECH CENTER 1600/2940

JUN 03 2002

RECEIVED

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
de	AJ	BUSCIGLIO J, ET AL. (1193) "Generation of b-amyloid in the secretory pathway in neuronal and nonneuronal cells" Proc. Natl. Acad. Sci. 90, 2092-2096	<input type="checkbox"/>
	AK	GEGEDDES JW ET AL. (1999) "N-terminus truncated b-amyloid peptides and C-terminus truncated secreted forms of of anyloid precursor protein: distinct roles in the pathogenesis of Alzheimer's disease" Neurobiol of Aging 20, 75-79.	<input type="checkbox"/>
	AL	HAAS C ET AL. (1992) "Amyloid b-peptide is produced by cultured cells during normal metabolism" Nature 359, 322-325	<input type="checkbox"/>
	AM	HAAS C ET AL. (1993) "Cellular processing of β amyloid precursor protein and the genesis of amyloid β -peptide." Cell 75, <1039-1042	<input type="checkbox"/>
	AN	HIGGINS LS ET AL. (1996) "p3 b amyloid peptide has a unique and potentially pathogenic immunohistochemical profile in Alzheimer's disease brain." Am. J. Pathol 149, 585-596	<input type="checkbox"/>
	AO	JOHNSON-WOOD K. ET AL. "Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease" Proc Natl. Acad. Sci U.S.A. 1997 Feb 18;94 (4): 1550-5	<input type="checkbox"/>
	AP	LALOWSKI M (1996) "The nonamyloidogenic p3 fragment (amyloid β 17-42) is a major constituent of Down's syndrome cerebellar preamyloid." J Biol Chem 271, 33623-31	<input type="checkbox"/>
	AQ	LARNER AJ (1999) "Hypothesis: amyloid b peptides truncated at the N-terminus contribute to the pathogenesis of Alzheimer's disease." Neurobiol. Of Aging 20, 65-69.	<input type="checkbox"/>
	AR	MASTERS CL ET AL. (1985) "Amyloid plaque core protein in Alzheimer's disease and Down syndrome." Proc. Natl. Acad. Sci. 82, 4245-9	<input type="checkbox"/>
	AS	MILLER DL ET AL. (1994) "Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease." Archives of Biochemistry and Biophysics 301, 41-52	<input type="checkbox"/>
	AT	NASLUND ET AL. (1994) "Relative abundance of Alzheimer A β amyloid peptide variants in Alzheimer disease and normal aging." Proc. Natl. Acad. Sci. USA 91, 8378-8382	<input type="checkbox"/>
	AU	PIKE CJ ET AL. (1995) "Amino-terminal deletions enhance aggregation of β -amyloid peptides in vitro." J Biol Chem 270, 23895-8	<input type="checkbox"/>
	AV	SEUBERT ET AL. (1992) "Isolation and quantification of soluble Alzheimer's β -peptide from biological fluids." Nature 359, 325-327	<input type="checkbox"/>
	AW	VIGO-PELFREY C ET AL. (1993) "Characterization of beta-amyloid peptide from human cerebrospinal fluid." J Neurochem 61, 1965-8	<input type="checkbox"/>
	AX	HANAN, Ellat et al., "Inhibitory effect of monoclonal antibodies on Alzheimer's Beta-amyloid peptide aggregation" INT. J. EXP. CLIN. INVEST., vol 3, pp. 130-133 (1996).	<input type="checkbox"/>
de	AY	SOLOMON, Beka et al., "Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer Betaamyloid peptide", PROC. NATL. ACAD. SCI. USA, vol. 93, pp 452-455 (1996)	<input type="checkbox"/>

Please type a plus sign (+) inside this box →



Approved for use through 10/31/99. OMB 0651-0031
 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/08A (10-96)

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/402,820
Filing Date	October 12, 1999
First Named Inventor	CHAIN, Daniel G.
Group Art Unit	1543
Examiner Name	P. Duffy
Attorney Docket Number	P-4815-US

TECH CENTER 1600/2900

JUN 03 2002

RECEIVED

Sheet	3	Of	4
de	AZ	SOLOMON, Beka et al., "Disaggregation of Alzheimer Beta-amyloid by site-directed mAb.", PROC. NATL. ACAD. SCI. USA, vol. 94, pp 4109-4112 (1997)	
	BA	TSUZUKI et al., "amyloid beta protein in rot soleus muscle in chloroquine-induced myopathy using end-specific antibodies for A beta 40 and A beta 42: Immunohistochemical evidence for amyloid beta protein", <u>Neurosci Letters</u> 202 (1-2):77-80 (1995)	
	BB	TURNER et al., "Mayloids β 40 and β 42 Are Generated Intracellularly in Cultured Human Neurons and Their Secretion Increases with maturation", <u>J Biol Chem</u> 271 (15):8966:8970 (1996)	
	BC	YANAGISAWA et al., "Fractionation of Amyloid β protein ($A\beta$) in Alzheimer's Disease and Down's Syndrome Brains: Presence of Membrane-Bound $A\beta$ ", <u>Ann NY Acad Sci</u> 786:184-194 (1996)	
	BD	GRAVINA et al., "Amyloid β Protein ($A\beta$) in Alzheimer's Disease Brain: Biochemical and Immunocytochemical Analysis with Antibodies Specific for Forms Ending at $A\beta$ 40 or $A\beta$ 42(43)", <u>J Biol Chem</u> 270 (13): 7013-7016 (1995)	
	BE	HARRINGTON et al., "Characterisation of an epitome specific to the neuron-specific Isoform of human enolase recognized by a monoclonal antibody raised against a synthetic peptide corresponding to the C-terminus of β /A-protein", <u>Biochim Biophys Acta</u> 1158:120-127 (1993)	
	BF	HIGGINS et al., "Transgenic Mouse Brain Histopathology Resembles Early Alzheimer's Disease", <u>Ann Neurol</u> 35:598-607 (1994)	
	BG	IWATSUBO et al., "Visualization of $A\beta$ 42 (43) and $A\beta$ 40 in Senile Plaques with End-Specific $A\beta$ Monoclonals: Evidence that an Initially Deposited species is $A\beta$ 42(43) <u>Neuron</u> 13:45-53 (1994)	
	BH	IWATSUBO et al., "Amyloid β protein ($A\beta$) Deposition: $A\beta$ 42 (43) Precedes $A\beta$ 40 in Down Syndrome". <u>Ann Neurol</u> 37:294-299 (1995)	
	BI	KONIG et al., "Development and Characterization of a Monoclonal Antibody 369. 2B Specific for the Carboxyl-Terminus of the β A4 Peptide", <u>Ann NY Acad Sci</u> 777:345-355 (1996)	
	BJ	MANN et al., "The extent of amyloid deposition in brain in patients with Down's Syndrome does not depend upon the apolipoprotein E genotype", <u>Neurosci Letters</u> 196 (1-2):105-108 (1995)	
	BK	MANN et al., "Predominant Deposition of Amyloid β 42 (43) in Plaques in Cases of Alzheimer's Disease and Hereditary Cerebral Hemorrhage Associated with Mutations in the Amyloid Precursor Protein Gene", <u>Am J Pathol</u> 148 (4):1257-1265 (1996)	
	BL	MANN et al., "Amyloid beta protein (A β) deposition in chromosome 14-linked Alzheimer's disease: predominance of A β 43 (43) <u>Ann Neurol</u> 40 (2):149-156 (1996)	
	BM	MURPHY et al., "Development of a Monoclonal Antibody Specific for the COOH-Terminal of β -Amyloid 1-42 and Its Immunohistochemical reactivity in Alzheimer's Disease and Related Disorders", <u>Am J Pathol</u> 144 (5):1082-1088 (1994)	
de	BN	NAKAMURA et al., "Carboxyl end-specific monoclonal antibodies to amyloid beta protein (A beta) subtypes (A beta 40 and A beta 42 (43) differentiate A beta in senile plaques and amyloid angiopathy in brains of aged cynomolgus monkeys." <u>Neurosci Letters</u> 201(2):151-154 (1996)	

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/402,820		
		Filing Date	October 12, 1999		
		First Named Inventor	CHAIN, Daniel G.		
		Group Art Unit	1543		
		Examiner Name	P. Duffy		
Sheet	4	Of	4	Attorney Docket Number	P-4815-US
<i>dc</i>	BO	SAIDO et al., "Spatial Resolution of Fodrin Proteolysis in Postischemic Brain", <u>J Biol Chem</u> 268(33): 25239-25243 (1993)			TECH CENTER 1000 2900
	BP	SUZUKI et al., "High Tissue Content of Soluble β 1-40 Is Linked to Cerebral Amyloid Angiopathy", <u>Am J Pathol</u> 145 (2):452-460 (1994)			
	BQ	TAMAOKA et al., "Amyloid β protein 1-42/43 ($A\beta$ 1-42/43) in cerebellar diffuse plaques: enzyme-linked immunosorbent assay and immunocytochemical study", <u>Brain Res</u> 679:151-156 (1995)			
	BR	DUERIASSE et al. Bio Techniques, 16 (3): 436-482			
	BS	JOHNSON-WOOD K. ET AL, "Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease," 1997, <u>Proc Natl Acad Sci U S A</u> Feb 18;94(4), pp 1550-5. <i>Duplicate</i>			

JUN 03 2002

RECEIVED

Examiner Signature	<i>Deborah Crench</i>	Date Considered	<i>5/21/04</i>
--------------------	-----------------------	-----------------	----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.